化合物Farampator T3957

Product Introduction
Bioactivity


英文名: Farampator

描述: Farampator (CX-691) 是 AMPA 受体正调节剂。

体外活性: CX691 attenuates a scopolamine-induced impairment of cued fear conditioning following acute administration (0.1 mg/kg p.o.) and a temporally induced deficit in novel object recognition following both acute (0.1 and 1.0 mg/kg p.o.) and sub-chronic (bi-daily for 7 days) administration (0.01, 0.03, 0.1 mg/kg p.o.). It also improves attentional set-shifting following sub-chronic administration (0.3 mg/kg p.o.). Farampator (500 mg) unequivocally improves short-term memory but appeares to impair episodic memory. Furthermore, it tends to decrease the number of switching errors in the CTMT. Drug-induced side effects (SEs) included headache, somnolence and nausea. Subjects with SEs has significantly higher plasma levels of farampator than subjects without SEs. Farampator has potential in treating disorders characterised by cognitive deficits such as Alzheimer's disease and schizophrenia.

体内活性: Farampator has potential in treating disorders characterised by cognitive deficits such as Alzheimer's disease and schizophrenia. CX691 attenuates a scopolamine-induced impairment of cued fear conditioning following acute administration (0.1 mg/kg p.o.) and a temporally induced deficit in novel object recognition following both acute (0.1 and 1.0 mg/kg p.o.) and sub-chronic (bi-daily for 7 days) administration (0.01, 0.03, 0.1 mg/kg p.o.). It also improves attentional set-shifting following sub-chronic administration (0.3 mg/kg p.o.)[1]. Farampator (500 mg) unequivocally improves short-term memory but appeares to impair episodic memory. Besides, it tends to decrease the number of switching errors in the CTMT. Drug-induced side effects (SEs) included headache, somnolence and nausea. Subjects with SEs has significantly higher plasma levels of farampator than subjects without SEs[2].

存储条件: Powder: -20°C for 3 years | In solvent: -80°C for 1 year

溶解度: DMSO : 50 mg/mL (216.21 mM)


关键字: inhibit | Org 24448 | Org-24448 | Inhibitor | iGluR | CX 691 | Farampator | CX691 | Ionotropic glutamate receptors

相关产品: CMPDA | NPS2390 | MMPIP hydrochloride | ABP688 | (1R,2S)-VU0155041 | MFZ 10-7 hydrochloride | LSN2463359 | S 18986 | HexylHIBO | ML289

相关库: Anti-Neurodegenerative Disease Compound Library | Drug Repurposing Compound Library | Neurotransmitter Receptor Compound Library | Anti-Cancer Drug Library | Membrane Protein-targeted Compound Library | Antidepressant Compound Library | Anti-Cancer Clinical Compound Library | Target-Focused Phenotypic Screening Library | NO PAINS Compound Library | Anti-Alzheimer's Disease Compound Library

化合物Farampator T3957信息由TargetMol中国为您提供，如您想了解更多关于化合物Farampator T3957报价、型号、参数等信息，欢迎来电或留言咨询。

注：该产品未在中华人民共和国食品药品监督管理部门申请医疗器械注册和备案，不可用于临床诊断或治疗等相关用途